- Conditions
- Bone; Disorder, Development and Growth
- Interventions
- Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- MEN1611, Trastuzumab, Fulvestrant
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri
- Conditions
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- Interventions
- GS-5829, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Stanford, California • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
- Conditions
- Menorrhagia
- Interventions
- Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
- Drug · Device
- Lead sponsor
- Abimbola Famuyide
- Other
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy Female Volunteers
- Interventions
- PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Coral Gables, Florida • Miami, Florida
- Conditions
- Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
- Interventions
- Futibatinib, Futibatinib plus Fulvestrant
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • San Francisco, California • Fort Myers, Florida + 12 more
- Conditions
- Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
- Interventions
- Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
- Drug · Device · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Normal Healthy Volunteers
- Interventions
- Toremifene, Placebo, GHRH/Ghrelin combined Injection
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 35 Years to 120 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
- Interventions
- Mirdametinib, Fulvestrant
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
- Interventions
- Drospirenone-Ethinyl Estradiol Oral Tablet
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Endometrioma
- Interventions
- Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Healthy Women, Female Contraception
- Interventions
- NES-E2 CVR
- Drug
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Menstruation Disturbances, Premenstrual Syndrome
- Interventions
- levonorgestrel/ethinyl estradiol
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 69
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more
- Conditions
- Solid Tumors
- Interventions
- Trametinib, Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Oklahoma City, Oklahoma
- Conditions
- Healthy Subjects
- Interventions
- lemborexant, Loestrin, famotidine, fluconazole
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
- Interventions
- LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Breast Neoplasms
- Interventions
- Neratinib, Fulvestrant, Trastuzumab, Tumor biopsy, Research blood sample
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
- Conditions
- Breast Cancer
- Interventions
- LEE011, BYL719, fulvestrant, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Postmenopause
- Interventions
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
- Conditions
- Primary Ovarian Insufficiency
- Interventions
- Transdermal Estrogen
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 11 Years to 18 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metastatic Breast Cancer
- Interventions
- Olaparib, 17b-estradiol
- Drug
- Lead sponsor
- Mary D Chamberlin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Aromatase inhibitor
- Drug
- Lead sponsor
- Marina N Sharifi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
- Behavioral · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington